BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 18448451)

  • 1. Practical guidance for the management of aromatase inhibitor-associated bone loss.
    Hadji P; Body JJ; Aapro MS; Brufsky A; Coleman RE; Guise T; Lipton A; Tubiana-Hulin M
    Ann Oncol; 2008 Aug; 19(8):1407-1416. PubMed ID: 18448451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment.
    Hadji P; Aapro MS; Body JJ; Bundred NJ; Brufsky A; Coleman RE; Gnant M; Guise T; Lipton A
    Ann Oncol; 2011 Dec; 22(12):2546-2555. PubMed ID: 21415233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance for the prevention of bone loss and fractures in postmenopausal women treated with aromatase inhibitors for breast cancer: an ESCEO position paper.
    Rizzoli R; Body JJ; DeCensi A; Reginster JY; Piscitelli P; Brandi ML;
    Osteoporos Int; 2012 Nov; 23(11):2567-76. PubMed ID: 22270857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidance for the management of breast cancer treatment-induced bone loss: a consensus position statement from a UK Expert Group.
    Reid DM; Doughty J; Eastell R; Heys SD; Howell A; McCloskey EV; Powles T; Selby P; Coleman RE
    Cancer Treat Rev; 2008; 34 Suppl 1():S3-18. PubMed ID: 18515009
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.
    Brufsky AM; Bosserman LD; Caradonna RR; Haley BB; Jones CM; Moore HC; Jin L; Warsi GM; Ericson SG; Perez EA
    Clin Breast Cancer; 2009 May; 9(2):77-85. PubMed ID: 19433387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A; Bundred N; Coleman R; Lambert-Falls R; Mena R; Hadji P; Jin L; Schenk N; Ericson S; Perez EA;
    Oncologist; 2008 May; 13(5):503-14. PubMed ID: 18515735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors and bone health.
    Bundred NJ
    Curr Opin Obstet Gynecol; 2009 Feb; 21(1):60-7. PubMed ID: 19125005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial.
    Goss PE; Hershman DL; Cheung AM; Ingle JN; Khosla S; Stearns V; Chalchal H; Rowland K; Muss HB; Linden HM; Scher J; Pritchard KI; Elliott CR; Badovinac-Crnjevic T; St Louis J; Chapman JA; Shepherd LE
    Lancet Oncol; 2014 Apr; 15(4):474-82. PubMed ID: 24636210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bone loss in postmenopausal breast cancer patients treated with aromatase inhibitors.
    Cepa M; Vaz C
    Acta Reumatol Port; 2015; 40(4):323-30. PubMed ID: 26922195
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline bone health status in multi-ethnic South African postmenopausal breast cancer patients at initiation of aromatase inhibitor therapy: A descriptive study.
    Baatjes KJ; Kotze MJ; McCaul M; Conradie M
    PLoS One; 2019; 14(4):e0214153. PubMed ID: 30939140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates may protect against bone loss in postmenopausal women with early breast cancer receiving adjuvant aromatase inhibitor therapy: results from a meta-analysis.
    Su G; Xiang Y; He G; Jiang C; Li C; Yan Z; Zhong Y
    Arch Med Res; 2014 Oct; 45(7):570-9. PubMed ID: 25450582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immediate Administration of Zoledronic Acid Reduces Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women With Early Breast Cancer: 12-month analysis of the E-ZO-FAST trial.
    Llombart A; Frassoldati A; Paija O; Sleeboom HP; Jerusalem G; Mebis J; Deleu I; Miller J; Schenk N; Neven P
    Clin Breast Cancer; 2012 Feb; 12(1):40-8. PubMed ID: 22014381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fracture Risk in Women with Breast Cancer Initiating Aromatase Inhibitor Therapy: A Registry-Based Cohort Study.
    Leslie WD; Morin SN; Lix LM; Niraula S; McCloskey EV; Johansson H; Harvey NC; Kanis JA
    Oncologist; 2019 Nov; 24(11):1432-1438. PubMed ID: 31292269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expert group consensus: prevention, diagnosis and treatment of bone loss and osteoporosis in postmenopausal breast cancer patients after aromatase inhibitor therapy].
    Xiu Bing-He ;
    Zhonghua Zhong Liu Za Zhi; 2013 Nov; 35(11):876-9. PubMed ID: 24447490
    [No Abstract]   [Full Text] [Related]  

  • 16. Reducing the risk of bone loss associated with breast cancer treatment.
    Hadji P
    Breast; 2007 Dec; 16 Suppl 3():S10-5. PubMed ID: 18023583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing bone loss in women with early-stage breast cancer receiving aromatase inhibitors.
    Brufsky AM
    Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S22-34. PubMed ID: 18282367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zoledronic acid for treatment of osteopenia and osteoporosis in women with primary breast cancer undergoing adjuvant aromatase inhibitor therapy: a 5-year follow-up.
    Majithia N; Atherton PJ; Lafky JM; Wagner-Johnston N; Olson J; Dakhil SR; Perez EA; Loprinzi CL; Hines SL
    Support Care Cancer; 2016 Mar; 24(3):1219-26. PubMed ID: 26298334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial.
    Greenspan SL; Vujevich KT; Brufsky A; Lembersky BC; van Londen GJ; Jankowitz RC; Puhalla SL; Rastogi P; Perera S
    Osteoporos Int; 2015 Jun; 26(6):1857-64. PubMed ID: 25792492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.